Oct 30, 2006 by Brian LawlerInterMune Plays "Let's Make a Deal"Intermune's deal with Roche could mean stiff competition for rival Vertex.
Oct 30, 2006 by Brian LawlerMedImmune's Mediocre QuarterThis biotech's products are far from immune to competition.
Oct 30, 2006 by Brian LawlerCelgene: Drug KingpinThe pharmaceutical company racks up bountiful sales.
Oct 30, 2006 by Brian LawlerMillennium Is So Last CenturyThe drug company looks expensive to at least one Fool.
Oct 30, 2006 by Brian LawlerSales Slow Down for Bristol-MyersPlavix isn't the only drug facing a challenging future.
Oct 30, 2006 by Brian LawlerBuilding a Future ShireADHD drugs are big for Shire now, but the long term isn't as clear.
Oct 30, 2006 by Brian LawlerReddy, Set, Go for Earnings GrowthWith margins tightening, Dr. Reddy's finds an Rx for success.
Oct 27, 2006 by Brian LawlerWake Up to SepracorIts insomnia drug is taking hold, and sales of its other drug jumped, too.
Oct 26, 2006 by Brian LawlerQLT Quickly Losing TractionThe biotech company gets hammered by a competitor's superior product.
Oct 26, 2006 by Brian LawlerGlaxo's Prescription for Sagging SalesIts upcoming blockbuster drugs should help reverse overall sales declines.
Oct 26, 2006 by Brian LawlerMarket Rejects AstraZeneca's RemedyInvestors pummel the pharmaceutical firm, despite its impressive results.
Oct 26, 2006 by Brian LawlerArena Stays in the GameDespite having only early-pipeline offerings, Arena gets a boost from Cramer.
Oct 25, 2006 by Brian LawlerEarnings Soothe ImClone InvestorsEnjoy the strong quarter while you can -- Icahn has arrived.
Oct 25, 2006 by Brian LawlerThe Medicines Company's Heartening ResultsAngiomax sales bolster the pharmaceutical's bottom line.
Oct 25, 2006 by Brian LawlerLifeCell Needs an Earnings TransplantThese troubles are more than skin-deep.
Oct 24, 2006 by Brian LawlerAmgen's Ho-Hum QuarterWith all the money flowing into its coffers, the company has no excuse not to start paying a dividend.
Oct 24, 2006 by Brian LawlerPlaying the AtheroGenics Waiting GameThe results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future.
Oct 23, 2006 by Brian LawlerMerck Mints MoneyThe pharmaceutical hangs on, despite ongoing Vioxx woes.
Oct 23, 2006 by Brian LawlerNo Slowing NovartisThe Swiss pharmaceutical company shows strength in nearly all its divisions.
Oct 23, 2006 by Brian LawlerMGI's Anonymous GrowthIf there's a value stock in the pharma world, this may be it.
